269 related articles for article (PubMed ID: 25810538)
1. Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.
Ternette N; Block PD; Sánchez-Bernabéu Á; Borthwick N; Pappalardo E; Abdul-Jawad S; Ondondo B; Charles PD; Dorrell L; Kessler BM; Hanke T
J Virol; 2015 Jun; 89(11):5760-71. PubMed ID: 25810538
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.
Hancock G; Morón-López S; Kopycinski J; Puertas MC; Giannoulatou E; Rose A; Salgado M; Hayton EJ; Crook A; Morgan C; Angus B; Chen F; Yang H; Martinez-Picado J; Hanke T; Dorrell L
J Int AIDS Soc; 2017 May; 20(1):21171. PubMed ID: 28537062
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
Hayton EJ; Rose A; Ibrahimsa U; Del Sorbo M; Capone S; Crook A; Black AP; Dorrell L; Hanke T
PLoS One; 2014; 9(7):e101591. PubMed ID: 25007091
[TBL] [Abstract][Full Text] [Related]
4. Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
Ondondo B; Brennan C; Nicosia A; Crome SJ; Hanke T
Vaccine; 2013 Nov; 31(47):5594-601. PubMed ID: 23831324
[TBL] [Abstract][Full Text] [Related]
5. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.
Rosario M; Borthwick N; Stewart-Jones GB; Mbewe-Mvula A; Bridgeman A; Colloca S; Montefiori D; McMichael AJ; Nicosia A; Quakkelaar ED; Drijfhout JW; Melief CJ; Hanke T
AIDS; 2012 Jan; 26(3):275-84. PubMed ID: 22095198
[TBL] [Abstract][Full Text] [Related]
6. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
[TBL] [Abstract][Full Text] [Related]
8. Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.
Ondondo B; Abdul-Jawad S; Bridgeman A; Hanke T
Clin Vaccine Immunol; 2014 Nov; 21(11):1565-72. PubMed ID: 25230940
[TBL] [Abstract][Full Text] [Related]
9. Direct interrogation of viral peptides presented by the class I HLA of HIV-infected T cells.
Yaciuk JC; Skaley M; Bardet W; Schafer F; Mojsilovic D; Cate S; Stewart CJ; McMurtrey C; Jackson KW; Buchli R; Olvera A; Cedeño S; Plana M; Mothe B; Brander C; West JT; Hildebrand WH
J Virol; 2014 Nov; 88(22):12992-3004. PubMed ID: 25165114
[TBL] [Abstract][Full Text] [Related]
10. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
[TBL] [Abstract][Full Text] [Related]
11. Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells.
Ternette N; Yang H; Partridge T; Llano A; Cedeño S; Fischer R; Charles PD; Dudek NL; Mothe B; Crespo M; Fischer WM; Korber BT; Nielsen M; Borrow P; Purcell AW; Brander C; Dorrell L; Kessler BM; Hanke T
Eur J Immunol; 2016 Jan; 46(1):60-9. PubMed ID: 26467324
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
Hanke T; Blanchard TJ; Schneider J; Ogg GS; Tan R; Becker M; Gilbert SC; Hill AV; Smith GL; McMichael A
J Gen Virol; 1998 Jan; 79 ( Pt 1)():83-90. PubMed ID: 9460927
[TBL] [Abstract][Full Text] [Related]
13. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
Im EJ; Nkolola JP; di Gleria K; McMichael AJ; Hanke T
Eur J Immunol; 2006 Oct; 36(10):2574-84. PubMed ID: 17013988
[TBL] [Abstract][Full Text] [Related]
14. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Mwau M; Cebere I; Sutton J; Chikoti P; Winstone N; Wee EG; Beattie T; Chen YH; Dorrell L; McShane H; Schmidt C; Brooks M; Patel S; Roberts J; Conlon C; Rowland-Jones SL; Bwayo JJ; McMichael AJ; Hanke T
J Gen Virol; 2004 Apr; 85(Pt 4):911-919. PubMed ID: 15039533
[TBL] [Abstract][Full Text] [Related]
15. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
[TBL] [Abstract][Full Text] [Related]
16. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.
Guerra S; González JM; Climent N; Reyburn H; López-Fernández LA; Nájera JL; Gómez CE; García F; Gatell JM; Gallart T; Esteban M
J Virol; 2010 Aug; 84(16):8141-52. PubMed ID: 20534857
[TBL] [Abstract][Full Text] [Related]
17. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
18. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.
Zhang X; Cassis-Ghavami F; Eller M; Currier J; Slike BM; Chen X; Tartaglia J; Marovich M; Spearman P
J Virol; 2007 Jul; 81(13):7022-33. PubMed ID: 17409140
[TBL] [Abstract][Full Text] [Related]
19. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling.
Meyer VS; Kastenmuller W; Gasteiger G; Franz-Wachtel M; Lamkemeyer T; Rammensee HG; Stevanovic S; Sigurdardottir D; Drexler I
J Immunol; 2008 Nov; 181(9):6371-83. PubMed ID: 18941228
[TBL] [Abstract][Full Text] [Related]
20. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
